SUPERNUS PHARMACEUTICALS, INC. Retained Earnings
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Retained Earnings of $457.21 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-03
- 2026-06-30: Retained Earnings (Accumulated Deficit) $457.21M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) $515.58M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $517.88M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $521.98M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | $457.21M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $515.58M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $517.88M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $521.98M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $567.10M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $544.60M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $556.43M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $541.10M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $502.60M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $482.69M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $482.56M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $481.39M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $497.36M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $498.19M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $481.25M 10-Q · filed 2023-11-08 | |
| 2022-09-30 | $455.76M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $454.01M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $446.15M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $379.92M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $377.48M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $355.92M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $332.19M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $326.50M 10-K · filed 2022-04-13 | |
| 2020-09-30 | $295.73M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $255.73M 10-Q · filed 2020-08-17 | |
| 2020-03-31 | $221.07M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $199.55M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $166.42M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $137.56M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $104.83M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $86.49M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $60.60M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $32.59M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $1.85M 10-Q · filed 2018-05-10 | |
| 2018-01-01 | -$24.50M 10-K · filed 2019-03-01 | |
| 2017-12-31 | -$26.82M 10-K · filed 2019-03-01 | |
| 2017-09-30 | -$40.48M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$56.44M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$73.81M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$84.29M 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$98.61M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | -$160.43M 10-Q/A · filed 2017-01-23 | -$129.64M 10-Q · filed 2016-08-05 |
| 2016-03-31 | -$170.68M 10-Q/A · filed 2017-01-20 | -$139.65M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$175.51M 10-K · filed 2017-03-16 | -$144.64M 10-K · filed 2016-03-09 |
| 2015-09-30 | -$182.36M 10-Q/A · filed 2017-01-20 | -$151.51M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$186.28M 10-Q/A · filed 2017-01-23 | -$155.73M 10-Q · filed 2015-08-07 |
| 2015-03-31 | -$188.72M 10-Q/A · filed 2017-01-20 | -$157.74M 10-Q · filed 2015-05-06 |
| 2014-12-31 | -$189.45M 10-Q/A · filed 2017-01-20 | -$158.66M 10-K · filed 2015-03-12 |
| 2014-09-30 | -$193.24M 10-Q/A · filed 2017-01-20 | -$163.01M 10-Q · filed 2014-11-12 |
| 2014-06-30 | -$190.87M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | -$194.07M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | -$178.53M 10-K · filed 2015-03-12 | |
| 2013-09-30 | -$156.12M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | -$132.03M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | -$104.67M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | -$86.25M 10-K · filed 2014-03-21 | |
| 2012-09-30 | -$72.74M 10-Q · filed 2012-11-02 | |
| 2012-06-30 | -$59.26M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | -$49.25M 10-Q · filed 2012-06-08 | |
| 2011-12-31 | -$39.97M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |